Q32 Bio Inc. Common Stock (QTTB)

Price$13.11

Value ScoreC

Growth ScoreA

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)490.70%

Price vs S&P 500 (4W)144.14%

VGM Score82.72

Market Capitalization$222.30M

P/E Ratio (Annual)7.45x

All Metrics

Book Value / Share (Quarterly)$3.17

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)155.81%

Cash Flow / Share (Quarterly)$-1.87

Price vs S&P 500 (YTD)286.72%

Net Profit Margin (TTM)107.43%

EPS (TTM)$2.29

10-Day Avg Trading Volume2.88M

EPS Excl Extra (TTM)$2.29

Revenue Growth (5Y)81.88%

EPS (Annual)$2.42

ROI (Annual)-255.53%

Net Profit Margin (5Y Avg)-2984.10%

Cash / Share (Quarterly)$3.47

P/E Basic Excl Extra (TTM)7.45x

P/E Normalized (Annual)7.45x

ROA (Last FY)-51.88%

EBITD / Share (TTM)$1.27

ROE (5Y Avg)-224.01%

Operating Margin (TTM)85.38%

Cash Flow / Share (Annual)$-5.65

P/B Ratio4.80x

P/B Ratio (Quarterly)2.03x

Net Income / Employee (Annual)$1,242,500

ROA (TTM)45.06%

EV / EBITDA (TTM)11.45x

EPS Incl Extra (Annual)$2.42

Current Ratio (Annual)5.13x

Quick Ratio (Quarterly)4.84x

3-Month Avg Trading Volume0.56M

52-Week Price Return612.50%

P/E Incl Extra (TTM)7.45x

Revenue / Employee (TTM)$2,239,000

P/S Ratio (Annual)4.14x

Asset Turnover (Annual)0.01x

52-Week High$14.85

Operating Margin (5Y Avg)-2631.48%

EPS Excl Extra (Annual)$2.42

CapEx CAGR (5Y)-67.85%

26-Week Price Return498.63%

Quick Ratio (Annual)4.92x

13-Week Price Return188.77%

Total Debt / Equity (Annual)2.29x

Current Ratio (Quarterly)5.36x

Enterprise Value$179.73M

Revenue / Share Growth (5Y)136.64%

Asset Turnover (TTM)0.87x

Revenue / Employee (Annual)$2,239,000

Pretax Margin (Annual)55.49%

Cash / Share (Annual)$6.50

3-Month Return Std Dev203.72%

Net Income / Employee (TTM)$1,242,500

ROE (Last FY)-840.37%

EPS Basic Excl Extra (Annual)$2.42

Total Debt / Equity (Quarterly)0.18x

EPS Incl Extra (TTM)$2.29

ROI (TTM)111.62%

P/S Ratio (TTM)4.14x

Pretax Margin (5Y Avg)-2497.64%

Revenue / Share (Annual)$4.36

Price vs S&P 500 (52W)588.13%

P/E Ratio (TTM)7.45x

Year-to-Date Return294.88%

5-Day Price Return12.44%

EPS Normalized (Annual)$2.42

ROA (5Y Avg)-56.34%

Net Profit Margin (Annual)55.49%

Month-to-Date Return18.64%

EBITD / Share (Annual)$1.27

Operating Margin (Annual)28.48%

ROI (5Y Avg)-107.04%

P/E Excl Extra (TTM)7.45x

LT Debt / Equity (Quarterly)0.04x

EPS Basic Excl Extra (TTM)$2.29

P/B Ratio (Annual)8.38x

Pretax Margin (TTM)107.43%

Book Value / Share (Annual)$0.42

Price vs S&P 500 (13W)180.51%

Beta0.28x

P/FCF (Annual)49.18x

Revenue / Share (TTM)$4.26

ROE (TTM)137.41%

52-Week Low$1.34

vGradeC

gGradeA

mGradeA

vgmGradeA

Show chart for

Earnings Surprise History

Q1 26-0.54est. -0.69

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
QTTBQ32 Bio Inc. Common Stock	C	A	A	$13.11
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Q32 Bio Inc is a clinical-stage biotechnology company developing antibody-based therapeutics for autoimmune and inflammatory diseases. The company targets key pathways in both adaptive immunity (T and B cells) and innate immunity to restore immune balance. Q32's approach is designed to provide safe and effective treatment options for patients with pathological immune dysfunction.